Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Tetraphase Pharmaceu (TTPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 167,038
  • Shares Outstanding, K 52,860
  • Annual Sales, $ 9,670 K
  • Annual Income, $ -114,750 K
  • 36-Month Beta 2.65
  • Price/Sales 16.46
  • Price/Cash Flow N/A
  • Price/Book 1.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.34
  • Number of Estimates 4
  • High Estimate -0.28
  • Low Estimate -0.40
  • Prior Year -0.63
  • Growth Rate Est. (year over year) +46.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.88 +10.42%
on 09/19/18
3.66 -13.11%
on 08/31/18
+0.04 (+1.27%)
since 08/21/18
3-Month
2.67 +19.10%
on 08/20/18
4.05 -21.48%
on 07/03/18
-0.81 (-20.30%)
since 06/21/18
52-Week
2.05 +55.12%
on 02/20/18
7.98 -60.15%
on 10/04/17
-3.66 (-53.51%)
since 09/21/17

Most Recent Stories

More News
SHAREHOLDER ALERT: ZN RMTI TTPH ABBV HMNY GDS PVG OPK USAT TRCO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

PVG : 8.15 (+1.75%)
HMNY : 0.01 (unch)
ZN : 1.02 (-0.97%)
RMTI : 4.39 (+4.03%)
USAT : 10.15 (+2.01%)
GDS : 34.60 (+1.02%)
ABBV : 92.90 (+0.24%)
OPK : 4.32 (-2.70%)
TRCO : 37.98 (+0.03%)
TTPH : 3.18 (+0.63%)
TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tetraphase Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tetraphase Pharmaceuticals, Inc. ("Tetraphase"...

TTPH : 3.18 (+0.63%)
EQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. - TTPH

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)...

TTPH : 3.18 (+0.63%)
Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA(TM) (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections

- Broad Product Label for Treatment of Complicated Intra-Abdominal Infections -

TTPH : 3.18 (+0.63%)
Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc.(TTPH)

Glancy Prongay & Murray LLP ("GPM")reminds investors of theSeptember 25, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased...

TTPH : 3.18 (+0.63%)
Tetraphase Pharmaceuticals to Present XERAVA(TM) (Eravacycline) and TP-6076 Data at IDWeek 2018

- Four Abstracts Selected for Poster Presentations -

TTPH : 3.18 (+0.63%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vuzix, Tetraphase, and LogMeIn and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Vuzix Corporation, Tetraphase Pharmaceuticals, Inc., and LogMeIn, Inc. Stockholders...

VUZI : 6.85 (+10.48%)
LOGM : 87.40 (+1.98%)
TTPH : 3.18 (+0.63%)
The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc.(TTPH)

Law Offices of Howard G. Smithreminds investors of the September 25, 2018deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Tetraphase...

TTPH : 3.18 (+0.63%)
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tetraphase Pharmaceuticals, Inc. (TTPH) and Lead Plaintiff Deadline - September 25, 2018

NEW YORK, NY / ACCESSWIRE / September 17, 2018 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. ("Tetraphase"...

TTPH : 3.18 (+0.63%)
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZN, RMTI, TTPH, HMNY and GDS

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

HMNY : 0.01 (unch)
ZN : 1.02 (-0.97%)
RMTI : 4.39 (+4.03%)
GDS : 34.60 (+1.02%)
TTPH : 3.18 (+0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade TTPH with:

Business Summary

Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug...

See More

Key Turning Points

2nd Resistance Point 3.36
1st Resistance Point 3.26
Last Price 3.18
1st Support Level 3.01
2nd Support Level 2.86

See More

52-Week High 7.98
Fibonacci 61.8% 5.71
Fibonacci 50% 5.01
Fibonacci 38.2% 4.32
Last Price 3.18
52-Week Low 2.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar